首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1475219

全球甲狀腺疾病治療市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

Global Thyroid Gland Disorder Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年04月01日 | 出版商:

Value Market Research | 英文 222 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

在2024年至2032年的研究期間，全球甲狀腺疾病治療市場的需求預計將達到4.29%的複合年成長率。

甲狀腺疾病治療是指旨在治療各種甲狀腺疾病的醫療干預和治療，例如甲狀腺功能減退症、甲狀腺功能亢進症、甲狀腺結節、甲狀腺腫、甲狀腺癌和自體免疫甲狀腺疾病（例如橋本甲狀腺炎、格雷夫茲病）。治療選擇可能包括藥物（例如甲狀腺激素替代療法、抗甲狀腺藥物）、放射性碘療法、甲狀腺切除術（手術切除甲狀腺）、射頻消融、乙醇消融和甲狀腺癌標靶治療。治療選擇取決於甲狀腺疾病的類型和嚴重程度以及患者個別因素，例如年齡、整體健康狀況和偏好。

市場動態

甲狀腺疾病（包括甲狀腺功能減退症、甲狀腺功能亢進症和甲狀腺結節）的發生率不斷上升，推動了對有效治療方案的需求，以控制症狀、使甲狀腺激素水平正常化並改善患者的生活品質。人口老化、缺碘、自體免疫疾病、環境污染物等因素導致甲狀腺疾病負擔日益加重。此外，醫療技術和診斷工具的進步使得準確的診斷和針對個別患者需求的個人化治療方法成為可能，推動甲狀腺疾病治療方式的創新。此外，醫療保健領域越來越重視以患者為中心的護理、共同決策和整體管理方法，鼓勵採用多學科治療策略，將藥物、生活方式改變、飲食干預和補充療法結合起來，以獲得最佳結果。

此外，病患教育措施、宣導工作和公共衛生運動提高了人們對甲狀腺疾病、症狀、危險因子和治療選擇的認知，使患者能夠及時尋求醫療照護並遵守規定的治療方案。隨著人們越來越認知到甲狀腺疾病是一個重要的公共衛生問題，以及對全面綜合醫療保健服務的需求不斷成長，隨著醫療保健提供者和製藥公司不斷創新以滿足患者和患者不斷變化的需求，甲狀腺疾病治療市場預計將繼續成長。然而，圍繞新治療方式和藥物配方的監管障礙和安全擔憂可能會挑戰未來幾年甲狀腺疾病治療市場的成長。此外，來自非專利替代品的競爭加劇和定價壓力可能會阻礙市場擴張。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球甲狀腺疾病治療市場的各個細分市場進行了包容性評估。甲狀腺疾病治療產業的成長和趨勢為本研究提供了整體方法。

市場區隔

甲狀腺疾病治療市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按指示

甲狀腺功能低下症
甲狀腺功能亢進症

依給藥途徑

口服
靜脈
其他

按配銷通路

批發商/分銷商
零售連鎖店
網上發行
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲甲狀腺疾病治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。甲狀腺疾病治療市場的主要參與者包括雅培、輝瑞、Lannett Company, Inc.、葛蘭素史克、默克、Mylan NV、艾伯維公司、安進。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：甲狀腺疾病治療公司的競爭格局

甲狀腺疾病治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
Abbott

公司簡介
公司收入
產品
最近的發展

Pfizer

公司簡介
公司收入
產品
最近的發展

Lannett Company Inc.

公司簡介
公司收入
產品
最近的發展

GlaxoSmithKline

公司簡介
公司收入
產品
最近的發展

Merck KGaA

公司簡介
公司收入
產品
最近的發展

Mylan NV

公司簡介
公司收入
產品
最近的發展

AbbVie Inc.

公司簡介
公司收入
產品
最近的發展

Amgen.

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112114332

The global demand for Thyroid Gland Disorder Treatment Market is presumed to reach with a CAGR of 4.29% under the study period 2024 - 2032.

Thyroid gland disorder treatment refers to medical interventions and therapies aimed at managing various thyroid conditions such as hypothyroidism, hyperthyroidism, thyroid nodules, goiter, thyroid cancer, and autoimmune thyroid disorders (e.g., Hashimoto's thyroiditis, Graves' disease). Treatment options may include medication (e.g., thyroid hormone replacement therapy, antithyroid medications), radioactive iodine therapy, thyroidectomy (surgical removal of the thyroid gland), radiofrequency ablation, ethanol ablation, and targeted therapies for thyroid cancer. Treatment selection depends on the type & severity of the thyroid disorder and individual patient factors such as age, overall health, and preferences.

MARKET DYNAMICS

The rising incidence of thyroid disorders, including hypothyroidism, hyperthyroidism, and thyroid nodules, drives the demand for effective treatment options to manage symptoms, normalize thyroid hormone levels, and improve patients' quality of life. Factors such as the aging population, iodine deficiency, autoimmune diseases, and environmental pollutants contribute to the increasing burden of thyroid diseases. Additionally, advancements in medical technology and diagnostic tools enable accurate diagnosis and personalized treatment approaches tailored to individual patient needs, driving innovation in thyroid gland disorder treatment modalities. Moreover, the growing emphasis on patient-centric care, shared decision-making, and holistic management approaches in healthcare encourages the adoption of multidisciplinary treatment strategies that combine medication, lifestyle modifications, dietary interventions, and complementary therapies for optimal outcomes.

Furthermore, patient education initiatives, advocacy efforts, and public health campaigns raise awareness about thyroid disorders, symptoms, risk factors, and treatment options, enabling patients to seek timely medical attention and adhere to prescribed treatment regimens. With the increasing recognition of thyroid disorders as a significant public health concern and the growing demand for comprehensive and integrated healthcare services, the thyroid gland disorder treatment market is predicted to continue growing as healthcare providers and pharmaceutical companies innovate to address the evolving needs of patients and improve clinical outcomes. However, regulatory hurdles and safety concerns surrounding new treatment modalities and drug formulations may challenge the growth of the thyroid gland disorder treatment market in the coming years. Additionally, increasing competition from generic alternatives and pricing pressures could impede market expansion.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of thyroid gland disorder treatment. The growth and trends of thyroid gland disorder treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the thyroid gland disorder treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Indication

Hypothyroidism
Hyperthyroidism

By Route Of Administration

Oral
Intravenous
Others

By Distribution Channel

Wholesalers/Distributors
Retail Chain
Online Distribution
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Thyroid Gland Disorder Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Thyroid Gland Disorder Treatment market include Abbott, Pfizer, Lannett Company, Inc., GlaxoSmithKline, Merck KGaA, Mylan N.V., AbbVie Inc., Amgen. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. THYROID GLAND DISORDER TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Indication
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET ANALYSIS BY INDICATION

5.1. Overview By Indication
5.2. Historical and Forecast Data
5.3. Analysis By Indication
5.4. Hypothyroidism Historic and Forecast Sales By Regions
5.5. Hyperthyroidism Historic and Forecast Sales By Regions

6. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1. Overview By Route of Administration
6.2. Historical and Forecast Data
6.3. Analysis By Route of Administration
6.4. Oral Historic and Forecast Sales By Regions
6.5. Intravenous Historic and Forecast Sales By Regions
6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1. Overview By Distribution Channel
7.2. Historical and Forecast Data
7.3. Analysis By Distribution Channel
7.4. Wholesalers/Distributors Historic and Forecast Sales By Regions
7.5. Retail Chain Historic and Forecast Sales By Regions
7.6. Online Distribution Historic and Forecast Sales By Regions
7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE THYROID GLAND DISORDER TREATMENT COMPANIES

9.1. Thyroid Gland Disorder Treatment Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF THYROID GLAND DISORDER TREATMENT INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Abbott
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Pfizer
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Lannett Company Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. GlaxoSmithKline
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Merck KGaA
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Mylan N.V.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. AbbVie Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Amgen.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments